Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) investors are having a rough day as the company just reported results from its second phase 3 for fostamatinib in ITP.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced plans to build a commercial organization to support the potential launch of fostamatinib, its oral SYK inhibitor, for …
This week was a busy one for biopharma BD teams. Finallized on Sunday, Valeant (VRX) will pay $158 per share for Salix Pharmaceuticals (SLXP) in an all-cash …
